StockData
Protagonist Therapeutics, Inc logo

Protagonist Therapeutics, Inc (PTGX) stock

PTGXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 12/30199% above fair value
$124.67−0.16 (-0.13%)

Close on Nov 17, 2026Market cap $8.07BP/E 121.0Yield –

Protagonist Therapeutics EV/EBITDA

EV/EBITDA is enterprise value divided by EBITDA over the trailing twelve months.

Protagonist Therapeutics's EV/EBITDA was 132.6× on Nov 11, 2026, against 84.3× a year earlier. Over the last 2 years it ranged from 7.4× to 251.8×, with a median of 84.3×.

EV/EBITDA at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 2026132.6×−111.0
2025Dec 31, 2025243.5×+231.4
2024Dec 31, 202412.2×–

More Protagonist Therapeutics figures

See a number that looks wrong?